U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H37N5O3
Molecular Weight 455.593
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FELCISETRAG

SMILES

COC(=O)N1CCC(CN2CCC(CNC(=O)C3=CC=CC4=C3NC(=N4)C(C)C)CC2)CC1

InChI

InChIKey=MZOITCJKGUIQEI-UHFFFAOYSA-N
InChI=1S/C25H37N5O3/c1-17(2)23-27-21-6-4-5-20(22(21)28-23)24(31)26-15-18-7-11-29(12-8-18)16-19-9-13-30(14-10-19)25(32)33-3/h4-6,17-19H,7-16H2,1-3H3,(H,26,31)(H,27,28)

HIDE SMILES / InChI

Molecular Formula C25H37N5O3
Molecular Weight 455.593
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

TD 8954 (also known as TAK 954) is a selective serotonin 5-HT(4) receptor agonist. It is known a potential role for potent and efficacious 5-HT(4) receptor agonists in the treatment of Alzheimer's disease (AD). TD 8954 participated in phase I clinical trials to study its potential role in the treatment of AD. However, this study was discontinued. In addition, TD 8954 is involved in phase II clinical trials to investigate its effect on gastrointestinal and colonic transit in diabetic or idiopathic gastroparesis participants and for the prophylaxis and treatment of postoperative gastrointestinal dysfunction in participants undergoing large- and small-bowel resection.

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Participation of 5-HT3, 5-HT4, and nicotinic receptors in the peristaltic reflex of guinea pig distal colon.
1996 Nov
Signal transduction pathways for serotonin as an intestinal secretagogue.
1997 Oct
Serotonin: a mediator of the brain-gut connection.
2000 Oct
Rationale for using serotonergic agents to treat irritable bowel syndrome.
2005 Apr 1
The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
2007 Jan
The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties.
2011
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
2013 Jul 15
Patents

Sample Use Guides

In Vivo Use Guide
TAK-954 0.1; 0.3; 1 milligram (mg), 60-minute infusion, intravenous (IV), once daily for up to 3 days.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Mon Oct 21 20:20:08 UTC 2019
Edited
by admin
on Mon Oct 21 20:20:08 UTC 2019
Record UNII
35F0Y2W16Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FELCISETRAG
INN  
Official Name English
TAK-954
Code English
1-PIPERIDINECARBOXYLIC ACID, 4-((4-((((2-(1-METHYLETHYL)-1H-BENZIMIDAZOL-7-YL)CARBONYL)AMINO)METHYL)-1-PIPERIDINYL)METHYL)-, METHYL ESTER
Systematic Name English
FELCISETRAG [INN]
Common Name English
TD-8954
Code English
Code System Code Type Description
CAS
916075-84-8
Created by admin on Mon Oct 21 20:20:08 UTC 2019 , Edited by admin on Mon Oct 21 20:20:08 UTC 2019
PRIMARY
PUBCHEM
11961293
Created by admin on Mon Oct 21 20:20:08 UTC 2019 , Edited by admin on Mon Oct 21 20:20:08 UTC 2019
PRIMARY
INN
11124
Created by admin on Mon Oct 21 20:20:08 UTC 2019 , Edited by admin on Mon Oct 21 20:20:08 UTC 2019
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Comments Maximum compound-evoked response 83% expressed as a percentage of the maximum response evoked by 5-HT.
BINDING
EC50
TARGET -> AGONIST
BINDING
Ki
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
PERMEABILITY PHARMACOKINETIC